search
Back to results

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (GABRINOX-ART)

Primary Purpose

Locally Advanced Pancreatic Adenocarcinoma

Status
Recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Gabrinox
MRI-GUIDED STEREOTACTIC RADIOTHERAPY
Sponsored by
Institut du Cancer de Montpellier - Val d'Aurelle
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Locally Advanced Pancreatic Adenocarcinoma focused on measuring Pancreatic, cancer

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient aged from 18 to 75 years at the date of signature of the consent form
  2. Histologically or cytologically proven pancreatic adenocarcinoma
  3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  4. Non-resectable tumour according to the National Comprehensive Cancer Network (NCCN) 1.2015 recommendations after external review of imaging data by multidisciplinary experts.
  5. Non-metastatic cancer confirmed by thorax-abdomen-pelvis computerized tomography (CT) scan and liver MRI
  6. SMART feasibility confirmed by centralized review
  7. Uracilemia < 16 ng/ml
  8. Hematological assessment within 14 days before inclusion, defined by:

    • Neutrophils ≥ 2 000/mm3 (2 × 109/L);
    • Platelets ≥ 100 000/mm3 (100 × 109/L);
    • Hemoglobin ≥ 9 g/dl
  9. Liver function (within 14 days before inclusion) defined by:

    • ASpartate Transaminase (AST) and ALanine Transaminase (ALT) ≤ 2.5 x Upper Limit of Normal (ULN);
    • Total bilirubin ≤ 1.5 x ULN. Patients with a metallic biliary prosthesis due to biliary obstruction caused by the cancer may be included, if: a CT scan with injection of contrast medium and thin pancreas sections was performed before placing the biliary prosthesis, the bilirubin level after prosthesis fitting decreased to ≤20 m /L (≤34 μmol/l), and in the absence of cholangitis.
  10. Creatininaemia within the reference limits, or calculated clearance ≥50 ml/min for patients with a serum creatinine value above or below the reference values (clearance calculated using the Chronic Kidney Disease EPIdemiology collaboration (CKDEPI formula).
  11. Serum calcium AND magnesium AND potassium ≥ Lower Limit Normal (LLN and ≤ 1.2 x Upper Limit Normal (ULN)
  12. Cancer Antigen (CA 19.9) <190 IU/mL (without cholestasis). Patients with CA 19.9 between 190 IU/mL and 500 IU/mL can be included if the Positron Emission Tomography (PET) scan and peritoneal MRI do not detect any distant fixation, indicative of metastasis. Patients with CA 19.9 ≥ 500 IU/mL cannot be included.
  13. Sexually active patients must use a contraceptive method considered adequate and suitable by the investigator during the entire period of administration of the study treatment and up to 3 months after the treatment end. Moreover, female and male patients must use a contraception method after the treatment end, as recommended by the Summary of the product characteristics (SmPC) or prescription information included in the study manual.
  14. Signature of the consent form before any study-specific procedure.
  15. Covered by the French health insurance.

Exclusion Criteria:

  1. Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, targeted therapy, experimental therapy)
  2. Gilbert's syndrome or homozygous Uridine DiPhosphate Glucuronosyl Transferase 1 A1 (UGT1A1 * 28)
  3. Other concomitant cancer or history of cancer, except for treated in situ cancer of the cervix , basal cell or squamous cell carcinoma, superficial bladder tumour (Ta, Tis, and T1), or good-prognosis tumour cured without chemotherapy and without signs of disease in the 3 years before inclusion
  4. History of radiotherapy that causes a foreseeable overlap with the radiotherapy treatment under study (history of abdominal irradiation)
  5. Patients with high cardiovascular risk, including, but not limited to, coronary stent or myocardial infarction in the past 6 months.
  6. Peripheral neuropathy ≥ grade 2
  7. ECG with QTcorrected (QTc) interval longer than 450 ms for men and longer than 470 ms for women
  8. Contraindication to MRI and MRI-guided radiotherapy
  9. History of chronic inflammatory disease of the colon or rectum
  10. Any other concomitant and not controlled serious illness or disturbance that may interfere with the patient's participation in the study and safety during the study (e.g. severe liver, kidney, lung, metabolic, or psychiatric disorder)
  11. Intolerance or allergy to one of the study drugs (gemcitabine, paclitaxel, oxaliplatin, irinotecan, 5-FU) or to one of their excipients (e.g. fructose) listed in the Contraindications or Warnings sections and Special precautions of the Summary of Product Characteristics (SmPC) or prescription information
  12. Legal incapacity (patient under guardianship or wardship)
  13. Pregnant or breastfeeding woman. Fertile women must have a negative pregnancy test (serum β-hCG) performed 72 hours before inclusion
  14. Patient using vitamin K antagonists (Coumadin…) (possible modification of the treatment before inclusion)
  15. Active and uncontrolled bacterial or fungal infection that requires systemic treatment.
  16. History or known HIV infection
  17. History of peripheral arterial disease (e.g. lameness, Buerger's disease).
  18. Patient who received a attenuated live vaccine in the 10 days before inclusion
  19. Patient with history of pulmonary fibrosis or interstitial pneumonia.
  20. Inability to attend the follow-up visits due to geographic, social or mental reasons.
  21. Participation in another clinical study with a research product during the last 30 days before inclusion.

Sites / Locations

  • Institut Paoli CalmettesRecruiting
  • Centre Georges-François LeclercRecruiting
  • CHU CarémeauRecruiting
  • CHU Saint-EloiRecruiting
  • Institut régional du Cancer de MontpellierRecruiting
  • Hôpital Pitié SalpétriêreRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Gabrinox followed by stereotactic radiotherapy

Arm Description

Gembrax: Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest Folfirinox: Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous

Outcomes

Primary Outcome Measures

Rate of non-progression at 4 months
(Sequence 1 success = chemotherapy) according to the RECIST v1.1 criteria
Acute gastrointestinal non-toxicity rate
Absence of toxicity of grade ≥3 related to radiotherapy within 90 days, evaluated using the NCI-CTCAE v5.0 classification (sequence 2 success = radiotherapy)

Secondary Outcome Measures

Assessment of adverse events due to chemotherapy by using the NCI-CTCAE version 5.0 scale
Adverse events of chemotherapy evaluated using the NCI-CTCAE v5.0 classification
Assessment of adverse events due to radiotherapy by using the NCI-CTCAE version 5.0
Adverse events of radiotherapy evaluated using the NCI-CTCAE v5.0 classification
Progression-free Survival (PFS)
Between the date of inclusion and the date of the first documented progression or the date of death from any cause
Overall Survival (OS)
Interval between the date of inclusion and the date of death from any cause
Resection rate
Percentage of patients who undergo tumour surgery up to 6 months post-radiotherapy
Healthy margin resection rate (R0)
Prognostic impact of CA 19-9 changes on survival
Quality of life by using the quality of life questionnaire score (QLQ-C30)
The EORTC QLQ-C30 uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.
Quality of life by using the quality of life questionnaire score (QLQ-PAN26)
The QLQ-PAN26 uses for the question 31 to 56 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much").
Assessment of adverse events by using the NCI-CTCAE version 5.0 scale
From inclusion of first patient until the end of treatment
Correlation of planning target volume (PTV) coverage and dose received by the gross tumor volume (GTV) with progression free survival
End of radiotherapy
Correlation of planning target volume (PTV) coverage and dose received by the gross tumor volume (GTV) with overall survival
End of radiotherapy
Correlation of the dose received by organs at risk (duodenum, small intestine, stomach, colon) with the appearance of gastrointestinal toxicities
End of radiotherapy
Summation of the dosimetric results in terms of dose/volume for the adaptive radiotherapy sessions and comparison with the predicted dosimetry
End of radiotherapy
Coverage of the planning targeted volume (PTV) by the prescription dose
End of radiotherapy
Dose received by the gross total volume
End of radiotherapy
Progression-free Survival (PFS)
Between the radiotherapy start date and the date of the first documented progression or the date of death from any cause
Overall Survival (OS)
Interval between the radiotherapy start date and the date of death from any cause
Local disease control
Interval between the radiotherapy start date and the date of local progression of the disease

Full Information

First Posted
September 24, 2020
Last Updated
September 25, 2023
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
search

1. Study Identification

Unique Protocol Identification Number
NCT04570943
Brief Title
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Acronym
GABRINOX-ART
Official Title
Phase II Study to Assess the Interest of a Sequential Treatment With Gemcitabine/Nab-paclitaxel (GEMBRAX) and Then FOLFIRINOX Followed by Stereotactic Magnetic Resonance-guided Adaptive Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 15, 2020 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
October 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma. The study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy by Gabrinox regimen.
Detailed Description
Pancreatic cancer was the third cause of death by cancer worldwide in 2016, surpassing breast cancer. It is estimated that in 2030, pancreatic cancer will become the second cause of death by cancer after lung cancer. Its prognosis is very poor, with an overall survival (OS) at 5 years, all stages included, of 5.5%. According to the French cancer registry network (FRANCIM), its incidence has more than doubled in men and women between 1990 and 2018. The world standardized incidence rates for men and women were 5.2% and 2.7% in 1990 and 11% and 7% in 2018, respectively. This means a yearly annual increase of 2.7 for men and of 3.8 for women. The often late diagnosis, in 50% of cases at stage 4, and the limited treatment options explain the very low survival rate at 5 years. Currently, only surgery associated with adjuvant chemotherapy for 6 months allows doubling this survival rate. However, this situation concerns only 20% of cases. Indeed, 50% of pancreatic cancers are discovered at stage 4, and in 30% of patients cancer is detected when not resectable and non-metastatic (i.e. borderline resectable or locally advanced). To make an unresectable cancer resectable is one of the therapeutic strategies under development. However, treatment of locally advanced pancreatic cancer (LAPC) is not standardized. Chemotherapy is a used strategy, but 30% of cases will progress to metastatic disease. Therefore, the need in LAPC to control not only the local disease but also micro-metastases has led to the development of combined strategies with chemotherapy and optimal radiotherapy. For LAPC, chemotherapy is based on two drug combinations that are classically used for the first-line treatment of metastatic disease: FOLFIRINOX (FFX) (association of 5FU, Oxaliplatin and Irinotecan) and GEMBRAX (GA) (association of gemcitabine and nab-paclitaxel). Their association has been validated by phase 3 studies showing that compared with gemcitabine alone, they allow increasing the response rate by three times (30%), and almost doubling the median survival and progression-free survival, but with higher grade 3 hematologic and neurological toxicities. FFX and GA have been assessed also in LAPC. Retrospective studies confirmed the high response rate, 30 to 80% according to the study, and a median survival of 9 to 30 months. Recently, two phase 2 studies, evaluated GA alone and GA followed by FFX, respectively, for LAPC, and confirmed the efficacy, with a response rate of 30% and a secondary resection rate of 15% and 30.6%, respectively. Moreover, in patients who underwent tumour resection after treatment, survival was longer than in those not operated (27.4 vs 14.2 months; Hazard Ratio (HZ) = 0.45; p = 0.0035). Overall Survival (OS) (n= 165 patients) was 17.2 months. GABRINOX is a sequential treatment with GA and then FFX with the aim of limiting chemoresistance, decreasing toxicities and improving dose intensity. The feasibility and tolerance of this approach as first-line treatment of metastatic disease were validated in a phase 1 study, and its efficacy in a phase 2 study in which the primary objective was reached: objective response rate of 64.9%, disease control rate of 84.2%, progression-free survival (PFS) of 10.5 months, and Overall Survival (OS) of 15.1 months. Its tolerance profile is favorable with lower percentages of patients with neutropenia (34.5%), febrile neutropenia (3.5%), and neurotoxicity (5.2%). The role of chemo-radiotherapy for LAPC remains controversial. Many old studies showed the interest of this technique for the local and global control in patients with pancreatic cancer. However, a phase 3 study compared the efficacy of chemo-radiotherapy versus chemotherapy alone in patients without disease progression after chemotherapy with a regimen that is currently considered not optimal (i.e. gemcitabine with/without erlotinib). Although OS (the main endpoint) did not improve in the chemo-radiotherapy arm compared with the chemotherapy arm, PFS was significantly increased in the chemo-radiotherapy arm with a longer period without treatment (6.1 vs 3.7 months, P = 0.02) and a lower percentage of patients with locoregional progression (32% vs 46%, P =0.03). This confirms that radiotherapy is an effective treatment in pancreatic adenocarcinoma, but that the current delivery modalities do not allow significantly improving the patient prognosis. Indeed, the study used 3D conformal radiotherapy with conventional doses and classical fractioning. Retrospective and phase 1 and 2 studies that used more optimized techniques and higher doses reported better local disease control, but without an important impact on survival. Moreover, some studies suggest significant toxicity, particularly in gastrointestinal organs. Intensity-modulated radiotherapy and integrated boost radiotherapy showed promising local control and survival results. This suggests an avenue for technological improvement and dose augmentation to improve patient prognosis. Stereotactic magnetic resonance-guided adaptive radiotherapy is a new modality for dose delivery that exploits Magnetic Resonance Imaging (MRI)-guided linear accelerators to better target the treatment volume, while optimizing the protection of organs at risk. The tumour localization in the pancreas seems to be particularly suitable for the utilization of MRI-guided linear accelerators because the radiotherapy doses are limited in function of the gastrointestinal organ tolerance: duodenum, stomach, small intestine, colon. Recently, the results of a retrospective, multicentre study on irradiation of patients with LAPC using Magnetic Resonance Imaging (MRIdian® Linac™; Viewray. The study shows that survival was improved in patients who received an augmented irradiation dose. Specifically, the 2-year OS rate was 49% for patients who received a dose higher than 70 Gy and 30% for patients who received a lower equivalent dose. The study did not report significant toxicity in patients who received high-dose radiotherapy according to the optimized modalities with daily dosimetric adjustment and target monitoring at each radiotherapy session. These data suggest that dose intensification and the stereotactic magnetic resonance-guided adaptive radiotherapy technique improve radiotherapy results; however, prospective studies are needed to confirm these data. Therefore, the phase 2 study GABRINOX-ART in which an intensified chemotherapy regimen (GABRINOX i.e GA followed by FFX) is followed by optimized adjusted radiotherapy (stereotactic magnetic resonance-guided adaptive radiotherapy) seems to be an interesting strategy to evaluate in locally advanced pancreatic cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Locally Advanced Pancreatic Adenocarcinoma
Keywords
Pancreatic, cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
103 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Gabrinox followed by stereotactic radiotherapy
Arm Type
Experimental
Arm Description
Gembrax: Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest Folfirinox: Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous
Intervention Type
Combination Product
Intervention Name(s)
Gabrinox
Intervention Description
Regimen: GEMBRAX Other Names: Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m² Regimen: FOLFIRINOX Other Names: Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m² Gembrax + Folfirinox = GABRINOX
Intervention Type
Radiation
Intervention Name(s)
MRI-GUIDED STEREOTACTIC RADIOTHERAPY
Intervention Description
Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox. Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended.
Primary Outcome Measure Information:
Title
Rate of non-progression at 4 months
Description
(Sequence 1 success = chemotherapy) according to the RECIST v1.1 criteria
Time Frame
4 months
Title
Acute gastrointestinal non-toxicity rate
Description
Absence of toxicity of grade ≥3 related to radiotherapy within 90 days, evaluated using the NCI-CTCAE v5.0 classification (sequence 2 success = radiotherapy)
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Assessment of adverse events due to chemotherapy by using the NCI-CTCAE version 5.0 scale
Description
Adverse events of chemotherapy evaluated using the NCI-CTCAE v5.0 classification
Time Frame
36 months
Title
Assessment of adverse events due to radiotherapy by using the NCI-CTCAE version 5.0
Description
Adverse events of radiotherapy evaluated using the NCI-CTCAE v5.0 classification
Time Frame
36 months
Title
Progression-free Survival (PFS)
Description
Between the date of inclusion and the date of the first documented progression or the date of death from any cause
Time Frame
Through study completion, an average of 72 months
Title
Overall Survival (OS)
Description
Interval between the date of inclusion and the date of death from any cause
Time Frame
Through study completion, an average of 72 months
Title
Resection rate
Description
Percentage of patients who undergo tumour surgery up to 6 months post-radiotherapy
Time Frame
From the end of radiotherapy (3 months) through 6 months post-radiotherapy
Title
Healthy margin resection rate (R0)
Time Frame
From the end of radiotherapy (3 months) through 6 months post-radiotherapy
Title
Prognostic impact of CA 19-9 changes on survival
Time Frame
Through study completion, an average of 36 months
Title
Quality of life by using the quality of life questionnaire score (QLQ-C30)
Description
The EORTC QLQ-C30 uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.
Time Frame
Through study completion, an average of 60 months
Title
Quality of life by using the quality of life questionnaire score (QLQ-PAN26)
Description
The QLQ-PAN26 uses for the question 31 to 56 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much").
Time Frame
Through study completion, an average of 60 months
Title
Assessment of adverse events by using the NCI-CTCAE version 5.0 scale
Description
From inclusion of first patient until the end of treatment
Time Frame
Through study completion, an average of 36 months
Title
Correlation of planning target volume (PTV) coverage and dose received by the gross tumor volume (GTV) with progression free survival
Description
End of radiotherapy
Time Frame
An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)
Title
Correlation of planning target volume (PTV) coverage and dose received by the gross tumor volume (GTV) with overall survival
Description
End of radiotherapy
Time Frame
An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)
Title
Correlation of the dose received by organs at risk (duodenum, small intestine, stomach, colon) with the appearance of gastrointestinal toxicities
Description
End of radiotherapy
Time Frame
An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)
Title
Summation of the dosimetric results in terms of dose/volume for the adaptive radiotherapy sessions and comparison with the predicted dosimetry
Description
End of radiotherapy
Time Frame
An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)
Title
Coverage of the planning targeted volume (PTV) by the prescription dose
Description
End of radiotherapy
Time Frame
An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)
Title
Dose received by the gross total volume
Description
End of radiotherapy
Time Frame
An average of 9 months after the beginning of treatment (chemotherapy then radiotherapy)
Title
Progression-free Survival (PFS)
Description
Between the radiotherapy start date and the date of the first documented progression or the date of death from any cause
Time Frame
Through study completion, an average of 68 months
Title
Overall Survival (OS)
Description
Interval between the radiotherapy start date and the date of death from any cause
Time Frame
Through study completion, an average of 72 months
Title
Local disease control
Description
Interval between the radiotherapy start date and the date of local progression of the disease
Time Frame
Through study completion, an average of 68 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient aged from 18 to 75 years at the date of signature of the consent form Histologically or cytologically proven pancreatic adenocarcinoma Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Non-resectable tumour according to the National Comprehensive Cancer Network (NCCN) 1.2015 recommendations after external review of imaging data by multidisciplinary experts. Non-metastatic cancer confirmed by thorax-abdomen-pelvis computerized tomography (CT) scan and liver MRI SMART feasibility confirmed by centralized review Uracilemia < 16 ng/ml Hematological assessment within 14 days before inclusion, defined by: Neutrophils ≥ 2 000/mm3 (2 × 109/L); Platelets ≥ 100 000/mm3 (100 × 109/L); Hemoglobin ≥ 9 g/dl Liver function (within 14 days before inclusion) defined by: ASpartate Transaminase (AST) and ALanine Transaminase (ALT) ≤ 2.5 x Upper Limit of Normal (ULN); Total bilirubin ≤ 1.5 x ULN. Patients with a metallic biliary prosthesis due to biliary obstruction caused by the cancer may be included, if: a CT scan with injection of contrast medium and thin pancreas sections was performed before placing the biliary prosthesis, the bilirubin level after prosthesis fitting decreased to ≤20 m /L (≤34 μmol/l), and in the absence of cholangitis. Creatininaemia within the reference limits, or calculated clearance ≥50 ml/min for patients with a serum creatinine value above or below the reference values (clearance calculated using the Chronic Kidney Disease EPIdemiology collaboration (CKDEPI formula). Serum calcium AND magnesium AND potassium ≥ Lower Limit Normal (LLN and ≤ 1.2 x Upper Limit Normal (ULN) Cancer Antigen (CA 19.9) <500 IU/mL (without cholestasis). Patients with CA 19.9 between 500 IU/mL and 1000 IU/mL can be included if the Positron Emission Tomography (PET) scan and peritoneal MRI (optional) do not detect any distant fixation, indicative of metastasis. Patients with CA 19.9 ≥ 1000 IU/mL cannot be included. Sexually active patients must use a contraceptive method considered adequate and suitable by the investigator during the entire period of administration of the study treatment and up to 6 months after the treatment end, for female and male patients. Signature of the consent form before any study-specific procedure. Covered by the French health insurance. Exclusion Criteria: Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, targeted therapy, experimental therapy) Gilbert's syndrome or homozygous Uridine DiPhosphate Glucuronosyl Transferase 1 A1 (UGT1A1 * 28) Other concomitant cancer or history of cancer, except for treated in situ cancer of the cervix , basal cell or squamous cell carcinoma, superficial bladder tumour (Ta, Tis, and T1), or good-prognosis tumour cured without chemotherapy and without signs of disease in the 3 years before inclusion History of radiotherapy that causes a foreseeable overlap with the radiotherapy treatment under study (history of abdominal irradiation) Patients with high cardiovascular risk, including, but not limited to, coronary stent or myocardial infarction in the past 6 months. Peripheral neuropathy ≥ grade 2 ECG with QTcorrected (QTc) interval longer than 450 ms for men and longer than 470 ms for women Contraindication to MRI and MRI-guided radiotherapy History of chronic inflammatory disease of the colon or rectum Any other concomitant and not controlled serious illness or disturbance that may interfere with the patient's participation in the study and safety during the study (e.g. severe liver, kidney, lung, metabolic, or psychiatric disorder) Intolerance or allergy to one of the study drugs (gemcitabine, Nab-paclitaxel, oxaliplatin, irinotecan, 5-FU) or to one of their excipients (e.g. fructose) listed in the Contraindications or Warnings sections and Special precautions of the Summary of Product Characteristics (SmPC) or prescription information Legal incapacity (patient under guardianship or wardship) Pregnant or breastfeeding woman. Fertile women must have a negative pregnancy test (serum β-hCG) performed 72 hours before inclusion Patient using vitamin K antagonists (Coumadin…) (possible modification of the treatment before inclusion) Active and uncontrolled bacterial or fungal infection that requires systemic treatment. Know active HIV infection History of peripheral arterial disease (e.g. lameness, Buerger's disease). Patient who received a attenuated live vaccine in the 10 days before inclusion Patient with history of pulmonary fibrosis or interstitial pneumonia. Inability to attend the follow-up visits due to geographic, social or mental reasons. Participation in another clinical study with a research product during the last 30 days before inclusion.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aurore MOUSSION, MD
Phone
0467612446
Ext
+33
Email
Aurore.Moussion@icm.unicancer.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fabienne Portalès, MD
Organizational Affiliation
Institut de Cancérologie de Montpellier (ICM)
Official's Role
Study Chair
Facility Information:
Facility Name
Institut Paoli Calmettes
City
Marseille
State/Province
Bouches-du-Rhône
ZIP/Postal Code
13009
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean Emmanuel MITRY, MD
Email
MITRYJE@ipc.unicancer.fr
Facility Name
Centre Georges-François Leclerc
City
Dijon
State/Province
Côte d'Or
ZIP/Postal Code
21079
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
François Ghiringhelli, MD
Email
FGhiringhelli@cgfl.fr
Facility Name
CHU Carémeau
City
Nîmes
State/Province
Gard
ZIP/Postal Code
30029
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stéphane Obled, MD
Email
stephane.OBLED@chu-nimes.fr
Facility Name
CHU Saint-Eloi
City
Montpellier
State/Province
Herault
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric Assénat, MD
Phone
04 67 33 67 33
Ext
+33
Email
e-assenat@chu-montpellier.fr
Facility Name
Institut régional du Cancer de Montpellier
City
Montpellier
State/Province
Hérault
ZIP/Postal Code
34298
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabienne Portalès, MD
Phone
0467612353
Ext
+33
Email
fabienne.portales@icm.unicancer.fr
Facility Name
Hôpital Pitié Salpétriêre
City
Paris
ZIP/Postal Code
75013
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Baptiste Bachet, MD
Email
jean-baptiste.bachet@aphp.fr

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28055103
Citation
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
Results Reference
background
PubMed Identifier
27551890
Citation
Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016 Sep-Oct;55(9-10):1158-1160. doi: 10.1080/0284186X.2016.1197419. Epub 2016 Aug 23.
Results Reference
background
PubMed Identifier
30575490
Citation
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
Results Reference
background
PubMed Identifier
21561347
Citation
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
Results Reference
background
PubMed Identifier
24131140
Citation
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.
Results Reference
background
PubMed Identifier
27160474
Citation
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6.
Results Reference
background
PubMed Identifier
31953079
Citation
Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, Lopez-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):285-294. doi: 10.1016/S2468-1253(19)30327-9. Epub 2020 Jan 14.
Results Reference
background
PubMed Identifier
23822606
Citation
Kim YJ, Lee WJ, Woo SM, Kim TH, Han SS, Kim BH, Moon SH, Kim SS, Koh YH, Park SJ, Kim JY, Kim DY, Park JW. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. Radiat Oncol. 2013 Jul 3;8:160. doi: 10.1186/1748-717X-8-160.
Results Reference
background
PubMed Identifier
21621866
Citation
Huang J, Robertson JM, Margolis J, Balaraman S, Gustafson G, Khilanani P, Nadeau L, Jury R, McIntosh B. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol. 2011 May;99(2):114-9. doi: 10.1016/j.radonc.2011.05.038. Epub 2011 May 27.
Results Reference
background
PubMed Identifier
23474363
Citation
Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6.
Results Reference
background
PubMed Identifier
26635481
Citation
Yang YF, Cao XH, Bao CE, Wan X. Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015 Nov 9;8:3315-22. doi: 10.2147/OTT.S91292. eCollection 2015.
Results Reference
background
PubMed Identifier
27139057
Citation
Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, Andre T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016 May 3;315(17):1844-53. doi: 10.1001/jama.2016.4324.
Results Reference
background
PubMed Identifier
28068239
Citation
Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):313-322. doi: 10.1016/j.ijrobp.2016.10.030. Epub 2016 Oct 24.
Results Reference
background
PubMed Identifier
31171025
Citation
Reyngold M, Parikh P, Crane CH. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Radiat Oncol. 2019 Jun 6;14(1):95. doi: 10.1186/s13014-019-1309-x.
Results Reference
background
PubMed Identifier
29189331
Citation
Crane CH, O'Reilly EM. Ablative Radiotherapy Doses for Locally Advanced: Pancreatic Cancer (LAPC). Cancer J. 2017 Nov/Dec;23(6):350-354. doi: 10.1097/PPO.0000000000000292.
Results Reference
background
PubMed Identifier
26678659
Citation
Acharya S, Fischer-Valuck BW, Kashani R, Parikh P, Yang D, Zhao T, Green O, Wooten O, Li HH, Hu Y, Rodriguez V, Olsen L, Robinson C, Michalski J, Mutic S, Olsen J. Online Magnetic Resonance Image Guided Adaptive Radiation Therapy: First Clinical Applications. Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):394-403. doi: 10.1016/j.ijrobp.2015.10.015. Epub 2015 Oct 17. Erratum In: Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):243.
Results Reference
background
PubMed Identifier
29114617
Citation
Fischer-Valuck BW, Henke L, Green O, Kashani R, Acharya S, Bradley JD, Robinson CG, Thomas M, Zoberi I, Thorstad W, Gay H, Huang J, Roach M, Rodriguez V, Santanam L, Li H, Li H, Contreras J, Mazur T, Hallahan D, Olsen JR, Parikh P, Mutic S, Michalski J. Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system. Adv Radiat Oncol. 2017 Jun 1;2(3):485-493. doi: 10.1016/j.adro.2017.05.006. eCollection 2017 Jul-Sep.
Results Reference
background
PubMed Identifier
30197095
Citation
Henke LE, Contreras JA, Green OL, Cai B, Kim H, Roach MC, Olsen JR, Fischer-Valuck B, Mullen DF, Kashani R, Thomas MA, Huang J, Zoberi I, Yang D, Rodriguez V, Bradley JD, Robinson CG, Parikh P, Mutic S, Michalski J. Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A 4.5-Year Clinical Experience. Clin Oncol (R Coll Radiol). 2018 Nov;30(11):720-727. doi: 10.1016/j.clon.2018.08.010. Epub 2018 Sep 7.
Results Reference
background
PubMed Identifier
29277446
Citation
Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, Green O, Michalski J, Mutic S, Parikh P, Olsen J. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018 Mar;126(3):519-526. doi: 10.1016/j.radonc.2017.11.032. Epub 2017 Dec 23.
Results Reference
background
PubMed Identifier
31036034
Citation
Boldrini L, Cusumano D, Cellini F, Azario L, Mattiucci GC, Valentini V. Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls. Radiat Oncol. 2019 Apr 29;14(1):71. doi: 10.1186/s13014-019-1275-3.
Results Reference
background
PubMed Identifier
30825964
Citation
Bohoudi O, Bruynzeel AME, Meijerink MR, Senan S, Slotman BJ, Palacios MA, Lagerwaard FJ. Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. Radiother Oncol. 2019 Mar;132:16-22. doi: 10.1016/j.radonc.2018.11.019. Epub 2018 Dec 20.
Results Reference
background
PubMed Identifier
30149192
Citation
El-Bared N, Portelance L, Spieler BO, Kwon D, Padgett KR, Brown KM, Mellon EA. Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer. Pract Radiat Oncol. 2019 Jan;9(1):e46-e54. doi: 10.1016/j.prro.2018.08.010. Epub 2018 Aug 25.
Results Reference
background
PubMed Identifier
29765792
Citation
Luterstein E, Cao M, Lamb J, Raldow AC, Low DA, Steinberg ML, Lee P. Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach. Cureus. 2018 Mar 14;10(3):e2324. doi: 10.7759/cureus.2324.
Results Reference
background
PubMed Identifier
29573744
Citation
Olberg S, Green O, Cai B, Yang D, Rodriguez V, Zhang H, Kim JS, Parikh PJ, Mutic S, Park JC. Optimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT) of pancreatic cancer. Radiat Oncol. 2018 Mar 24;13(1):51. doi: 10.1186/s13014-018-1000-7.
Results Reference
background
PubMed Identifier
30174107
Citation
Tyran M, Jiang N, Cao M, Raldow A, Lamb JM, Low D, Luterstein E, Steinberg ML, Lee P. Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. Radiother Oncol. 2018 Nov;129(2):319-325. doi: 10.1016/j.radonc.2018.08.009. Epub 2018 Aug 30.
Results Reference
background
PubMed Identifier
30932367
Citation
Rudra S, Jiang N, Rosenberg SA, Olsen JR, Roach MC, Wan L, Portelance L, Mellon EA, Bruynzeel A, Lagerwaard F, Bassetti MF, Parikh PJ, Lee PP. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019 May;8(5):2123-2132. doi: 10.1002/cam4.2100. Epub 2019 Apr 1.
Results Reference
background

Learn more about this trial

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

We'll reach out to this number within 24 hrs